Jeremy Paul Tervo

Mr. Jeremy Paul Tervo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
JTJeremy Paul Tervo
Jeremy Paul Tervo
EDEmily DiMango
Emily DiMango
David A. GudisDavid A. Gudis
David A. Gudis
CKClaire Keating
Claire Keating
YZYuan Zhang
Yuan Zhang
JOJonathan B. Overdevest
Jonathan B. Overdevest

6 May 2024 in World Journal of Otorhinolaryngology - Head and Neck Surgery
Verified
Journal Article
Open access
JTJeremy Paul Tervo
Jeremy Paul Tervo
PJPatricia T. Jacobson
Patricia T. Jacobson
BVBrandon J. Vilarello
Brandon J. Vilarello
TSTiana M. Saak
Tiana M. Saak
FCFrancesco F. Caruana
Francesco F. Caruana
JOJonathan B. Overdevest
Jonathan B. Overdevest
Objectives: Persistent olfactory dysfunction (OD) following loss of smell associated with SARS‐CoV‐2 infection is a major feature of long COVID. Perspectives on the prevalence of persistent OD predominantly rely on self‐reported olfactory function. Few studies have tracked longitudinal rates of recovery using psychophysical assessment among patients presenting for evaluation of persistent OD beyond a window of acute recovery. Data anchored in standardized testing methods are needed to counsel patients who fail to acutely regain their sense of smell. This study aims to quantify the degree of persistent OD in post‐COVID‐19 patients who experience subjective and psychophysical OD.Methods: We grouped participants presenting for OD evaluation into cohorts based on both subjective and psychophysical olfactory status at a baseline assessment and assessed their olfactory abilities with a visual analogue scale and the Sniffin' Sticks extended test at baseline and 1‐year time points. Participants had confirmed a history of COVID‐19 by lab evaluation or clinical diagnosis if lab evaluation was not available.Results: Baseline olfactory evaluation was completed by 122 participants, 53 of whom completed the 1‐year follow‐up assessment. Among participants presenting with perceived OD, 74.5% had confirmed psychophysical OD at baseline, with 55.1% at 1‐year follow‐up. Participants had reliable trends in self‐rated versus psychophysically tested olfactory function at both time points. The total threshold, discrimination, and identification (TDI) score improved by +3.25 points in the cohort with psychophysical OD (p = 0.0005), with this improvement largely attributable to an increase in median threshold scores (+2.75 points; p = 0.0004).Conclusions: OD persists in a significant number of patients who fail to acutely recovery their sense of smell after COVID‐19, with many demonstrating lingering deficits at 1‐year. Improvements in threshold, but not discrimination or identification, most significantly mediate improvement of total TDI score at follow‐up.

26 October 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
BVBrandon Jose Vilarello
Brandon Jose Vilarello
PJPatricia T. Jacobson
Patricia T. Jacobson
JTJeremy Paul Tervo
Jeremy Paul Tervo
LGLiam W. Gallagher
Liam W. Gallagher
FCFrancesco Caruana
Francesco Caruana
JOJonathan B. Overdevest
Jonathan B. Overdevest
(1) Background: Reports suggest COVID-19-associated olfactory dysfunction (OD) may result in alterations in dietary behaviors and perceived weight change, but few studies using psychophysical evaluation of post-COVID-19-associated chemosensory dysfunction and body mass index (BMI) exist. The purpose of this study is to assess the impact of both quantitative and qualitative features of COVID-19-associated OD on BMI; (2) Methods: Recruitment of thirty-one participants with self-reported OD in the form of quantitative loss with and without qualitative features. Surveys with questions specific to qualitative olfactory function, Sniffin’ Sticks tests, and BMI measures were completed at two visits, one year apart. Group differences were assessed with Wilcoxon signed-rank tests and the Holm–Bonferroni method; (3) Results: Individuals with persistent quantitative OD (n = 15) and self-reported parosmia (n = 19) showed statistically significant increases in BMI after 1 year (p = 0.004, adjusted α = 0.0125; p = 0.011, adjusted α = 0.0167). Controls with transient quantitative OD (n = 16) and participants without self-reported parosmia (n = 12) showed no statistically significant changes in BMI over the same time period (p = 0.079, adjusted α = 0.05; p = 0.028, adjusted α = 0.025); (4) Conclusions: This study shows an association between COVID-19-associated OD and BMI, suggesting olfaction may play a role in altering dietary habits and nutrition in this population. Larger study cohorts are needed to further evaluate this relationship.

19 December 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
TSTiana Saak
Tiana Saak
JTJeremy Paul Tervo
Jeremy Paul Tervo
BVBrandon J. Vilarello
Brandon J. Vilarello
PJPatricia T. Jacobson
Patricia T. Jacobson
FCFrancesco Caruana
Francesco Caruana
JOJonathan B. Overdevest
Jonathan B. Overdevest
Background/Objectives: Olfactory dysfunction (OD) is associated with a variety of neurologic deficits and impacts socialization decisions, mood, and overall quality of life. As a common symptom comprising the long COVID condition, persistent COVID-19-associated olfactory dysfunction (C19OD) may further impact the presentations of neuropsychiatric sequelae. Our study aims to characterize the longitudinal burden of depression, anxiety, and neuropsychiatric symptoms in a population with C19OD. Methods: Individuals with perceived C19OD completed a psychophysical screening evaluation of their sense of smell using the comprehensive Sniffin’ Sticks olfactory assessment. Only those with validated psychophysical OD were included in this prospective longitudinal study for baseline and one-year follow-up. Participants also completed PHQ-9, Beck Anxiety Inventory (BAI), and neuropsychiatric symptom questionnaires at each time point. Anxiety, depression, and neuropsychiatric symptom prevalence was calculated and compared between time points with Pearson’s chi-squared, Fisher’s exact, and Wilcoxon rank sum tests. Results: Each neuropsychiatric symptom evaluated in this study was reported by 13–49% of longitudinal cohort participants at both baseline and follow-up, except for seizure (0% at baseline and follow-up) and word-finding difficulty (61–68% at baseline and follow-up). Word-finding and focus difficulties were the most commonly reported symptoms. In total, 41% of participants reported some level of depression at baseline and 38% of participants reported depression at one-year follow-up, while 29% and 27% of participants reported some level of anxiety at respective time points. Conclusions: Individuals with C19OD are at risk for developing persistent neuropsychiatric conditions. These neurologic and psychiatric sequelae are persistent with repeated longitudinal assessment, even at nearly 2.5 years following initial COVID-19 diagnosis.

25 December 2023 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
JMJessa Elaine Miller
Jessa Elaine Miller
JTJennifer L. Taylor‐Cousar
Jennifer L. Taylor‐Cousar
JOJonathan B. Overdevest
Jonathan B. Overdevest
AKAastha Khatiwada
Aastha Khatiwada
JMJess C. Mace
Jess C. Mace
DBDaniel M Beswick
Daniel M Beswick

14 January 2026 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
CLChristine M. Liu
Christine M. Liu
JFJakob Louis Fischer
Jakob Louis Fischer
JOJonathan B. Overdevest
Jonathan B. Overdevest
AZAnna C. Zemke
Anna C. Zemke
MSMatthew J. Strand
Matthew J. Strand
DBDaniel M Beswick
Daniel M Beswick
The 22-item sinonasal outcome test (SNOT-22) is widely used to evaluate quality of life (QOL) in cystic fibrosis chronic rhinosinusitis (CF-CRS) but lacks formal validation in people with CF (PwCF). This study explores the psychometric properties of the SNOT-22 following elexacaftor/tezacaftor/ivacaftor (ETI) administration. Data from three prospective observational cohort studies investigating the impact of ETI on CF-CRS were pooled across four U.S. centers and used for validity assessments. SNOT-22 scores, Lund-Mackay (LM) computed tomography (CT) sinus scores, and Cystic Fibrosis Questionnaire-Revised (CFQ-R) scores were used to assess test-retest reliability, construct validity, and responsiveness to clinical change in SNOT-22 scores. Strong test-retest reliability was observed for the SNOT-22 during the first 6 months post-ETI (N = 53, all r ≥ 0.80, p < 0.001). SNOT-22 intraclass correlation coefficients were strong (0.883) at 3 and 6 months after ETI was initiated and moderate (0.693) across all time points. Mean individual scores in 20 SNOT-22 items decreased from baseline to post-ETI (90.1%, p < 0.05). Moderate convergent validity was observed between pre-treatment SNOT-22 scores and LM scores (r = -0.42, p = 0.002) and CFQ-R respiratory domain scores (r = -0.35, p = 0.025). The SNOT-22 is a valid, reliable, and responsive instrument for evaluating CRS-specific QOL in adults with CF, and functions effectively as a unidimensional construct across most of its 22 items.